FDA clears Sanofi for adults with cancer
FDA clears Sanofi-Aventis' Elitek for new use in adults undergoing cancer treatment
- On 6:58 pm EDT, Friday October 16, 2009
BRIDGEWATER, N.J. (AP) -- French drugmaker Sanofi-Aventis said Friday U.S. regulators approved its drug Elitek to treat complications from leukemia, lymphoma and other cancers in adults.
The Food and Drug Administration previously approved the drug for use in children in 2002.
The drug is designed to treat so-called tumor lysis syndrome, a buildup of byproducts from broken-down cells that usually occurs after cancer treatment. The disease often appears in patients receiving treatment for leukemia, lymphoma, and cancerous tumors.
Shares of Paris-based Sanofi-Aventis fell $1.81, or 4.5 percent, to close at $38.34.
Related Headlines
Related Blog Headlines
- The Top 10 Chilean Banks According to Assets - at Seeking Alpha
- Your First Move For Thursday March 19th - at CNBC
Sponsored Links
-
Trade Stocks? Try Currency Trading
Trade in a highly trending market 24-hrs a day, 5.5 days a week. GFT. -
Earn From 1.90% to 2.20% Apply Online
With GE Capital Corporation. Not An Offer Of Securities For Sale.
-
Buy Stocks for $4
No account or investment minimums. No inactivity fees. Start Today. -
Refinance Now at 4.25% Fixed
No hidden fees-4.4% APR! No obligation. Get 4 free quotes. No SSN req.
Tech Ticker Recent Posts
Add Alert Copyright © 2009 The Associated Press. All rights reserved. The information contained in the AP News report may not be published, broadcast, rewritten, or redistributed without the prior written authority of The Associated Press.